EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Zevra Therapeutics's Enterprise Value is $654.2 Mil.
Zevra Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $12.0 Mil. Therefore, Zevra Therapeutics's EV-to-FCF for today is 54.54.
The historical rank and industry rank for Zevra Therapeutics's EV-to-FCF or its related term are showing as below:
ZVRA'
s EV-to-FCF Range Over the Past 10 Years
Min: -188.27 Med: -5.82 Max: 55.85
Current: 54.54
During the past 13 years, the highest EV-to-FCF of Zevra Therapeutics was 55.85. The lowest was -188.27. And the median was -5.82.
ZVRA's EV-to-FCF is ranked worse than 79.51% of 327
companies
in the Biotechnology industry
Industry Median: 16.69
vs ZVRA: 54.54
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zevra Therapeutics's PE Ratio (TTM) for today is calculated as:
Zevra Therapeutics's share price for today is $14.44.
Zevra Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.990.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Zevra Therapeutics EV-to-FCF Related Terms
Zevra Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Zevra Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zevra Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zevra Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Zevra Therapeutics's EV-to-FCF falls into.
Zevra Therapeutics's current Enterprise Value is $654.2 Mil.
Zevra Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zevra Therapeutics (ZVRA) has a EV-to-FCF of 54.54 as of Jul. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zevra Therapeutics and its competitors. According to the industry distribution chart, Zevra Therapeutics ranks #260 out of 327 companies in the Biotechnology industry, placing it in the top 79.5%.
Is Zevra Therapeutics' EV-to-FCF too high?
Zevra Therapeutics' current EV-to-FCF is 54.54. The Biotechnology industry median EV-to-FCF is 16.69. Zevra Therapeutics' value of 54.54 is 226.8% above this industry median. Based on the distribution chart, Zevra Therapeutics ranks #260 out of 327 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zevra Therapeutics has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zevra Therapeutics' EV-to-FCF compare to DSGN and SPRY?
According to the Biotechnology industry distribution chart, Zevra Therapeutics ranks #260 out of 327 companies for EV-to-FCF. This places Zevra Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 16.69. Zevra Therapeutics' value of 54.54 is 226.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.69, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zevra Therapeutics's current EV-to-FCF of 54.54 is 226.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zevra Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zevra Therapeutics's current EV-to-FCF is 54.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zevra Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Zevra Therapeutics (ZVRA) is currently considered Possible Value Trap. The stock's GF Value™ is $22.86, compared to a current price of $14.44 — trading 36.8% below its estimated fair value. The current EV-to-FCF is 54.54 and 226.8% above the Biotechnology industry median of 16.69. Zevra Therapeutics' overall GF Score™ is 68/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Zevra Therapeutics (ZVRA), the current EV-to-FCF is 54.54 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zevra Therapeutics (ZVRA) Overvalued in 2026?
Based on GuruFocus' analysis, Zevra Therapeutics stock appears to be undervalued.
The current stock price of $14.44 is trading 36.8% below its estimated GF Value™ of $22.86.
GuruFocus considers Zevra Therapeutics to be Possible Value Trap.
Key valuation signals for ZVRA:
EV-to-FCF: 54.54
GF Value™: $22.86 vs. price of $14.44 (36.8% below fair value)
Industry Position: 226.8% above the Biotechnology median (#260 of 327)
No single metric tells the full story. See the ZVRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
68GF Score
Get the complete analysis for ZVRA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZVRA has been successfully added to your 
